Latest progress on the molecular mechanisms of idiopathic pulmonary fibrosis

被引：0
|
作者：
Yue Fang
Jingya Tian
Yumei Fan
Pengxiu Cao
机构：
[1] Hebei Normal University,Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Sciences
[2] East China Normal University,Key Laboratory of Brain Functional Genomics of Ministry of Education, School of Life Sciences
[3] Hebei University,College of Chemistry and Environmental Sciences
来源：
Molecular Biology Reports | 2020年 / 47卷
关键词：
Idiopathic pulmonary fibrosis; Alveolar epithelial cells; Lung fibroblasts; Wnt; Mitochondria;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Idiopathic pulmonary fibrosis (IPF) is a serious life-threatening lung disease, and the median survival period of PF patients after diagnosis is only 2.5–3.5 years. At present, there are no effective drugs or therapeutics to reverse or even inhibit IPF. The main pathological characteristics of pulmonary fibrosis (PF) include damage to alveolar epithelial cells, fibroblast activation and extracellular matrix accumulation, which gradually lead to damage to the lung structure and decreased lung function. It is important to understand the cellular and molecular mechanisms of PF comprehensively and clearly. In this paper, critical signaling pathways related to PF were reviewed to present updates on the molecular mechanisms of PF.
引用
收藏
页码：9811 / 9820
页数：9
相关论文
共 50 条
  • [1] Latest progress on the molecular mechanisms of idiopathic pulmonary fibrosis
    Fang, Yue
    Tian, Jingya
    Fan, Yumei
    Cao, Pengxiu
    MOLECULAR BIOLOGY REPORTS, 2020, 47 (12) : 9811 - 9820
  • [2] Molecular Mechanisms in Progressive Idiopathic Pulmonary Fibrosis
    Steele, Mark P.
    Schwartz, David A.
    ANNUAL REVIEW OF MEDICINE, VOL 64, 2013, 64 : 265 - 276
  • [3] Cellular and Molecular Mechanisms in Idiopathic Pulmonary Fibrosis
    Zhang, Yihang
    Wang, Jiazhen
    ADVANCES IN RESPIRATORY MEDICINE, 2023, 91 (01) : 26 - 48
  • [4] Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis
    Ma, Hongbo
    Wu, Xuyi
    Li, Yi
    Xia, Yong
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Integrated analysis of the molecular mechanisms in idiopathic pulmonary fibrosis
    Zhu, Ke
    Xu, Aiqun
    Xia, Wanli
    Li, Pulin
    Han, Rui
    Wang, Enze
    Zhou, Sijing
    Wang, Ran
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2021, 18 (15): : 3412 - 3424
  • [6] Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches
    Glass, Daniel S.
    Grossfeld, David
    Renna, Heather A.
    Agarwala, Priya
    Spiegler, Peter
    Kasselman, Lora J.
    Glass, Amy D.
    DeLeon, Joshua
    Reiss, Allison B.
    RESPIRATORY INVESTIGATION, 2020, 58 (05) : 320 - 335
  • [7] Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
    Ballester, Beatriz
    Milara, Javier
    Cortijo, Julio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (03)
  • [8] Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis
    Gharaee-Kermani, M
    Phan, SH
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (30) : 3943 - 3971
  • [9] New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis
    Fernandez, Isis E.
    Eickelberg, Oliver
    LANCET, 2012, 380 (9842): : 680 - 688
  • [10] IDIOPATHIC PULMONARY FIBROSIS PROGRESS AND CHALLENGE
    MARINELLI, WA
    CHEST, 1995, 108 (02) : 297 - 298
12345